Cellino

Cellino is a manufacturing-technology company, and it says so plainly: the product is the process and the hardware that runs it, not a therapy. That framing matters because it tells you who the buyer is — a biotech process team, a hospital system evaluating on-site production, or a strategist mapping the autologous supply chain — and who it isn't. The strongest technical claims on the site are specific enough to interrogate. Laser-generated bubbles that strip unwanted cells and pin cell density give you a control lever that manual culture doesn't have, and pairing that with a closed-loop, image-guided optical bioprocess is a coherent answer to run-to-run variability. The Cellinoverse, which simulates biomanufacturing in silico, is the more interesting piece commercially: if you can tune a process in simulation before it consumes a physical batch, your cost of process development drops and your iteration speed goes up. Nebula™ compresses the traditional infrastructure into modular cassettes, which is what makes either a distributed foundry model or a hospital-localized unit physically plausible. The self-sourced, patient-own cell approach eliminating immunosuppression is as much a market-access argument as a clinical one, and it is the reason the named target list runs as wide as it does — kidney disease, spinal cord injury, diabetes, Parkinson's, macular degeneration, congenital heart disease, muscular dystrophy, Alzheimer's, obesity, lung disease, urinary incontinence and infertility. The honest weaknesses are the ones a procurement team will hit first. Cellino publishes announcements rather than specifications: no throughput figures, no unit economics, no product datasheets, no release timelines attached to those twelve-plus conditions. A build-or-buy analysis cannot be finished from public material. Deploying or even properly evaluating the stack requires fluency across cell biology, process engineering, laser optics and machine learning simultaneously — a rare combination inside one organization, which is part of why partnership conversations rather than self-serve adoption are the realistic path. The most recent public evidence that the technology travels across patient backgrounds is the Polyphron collaboration of April 7, 2026; the Fast Company listing of March 24, 2026 is a credibility signal, not a procurement input. Neither substitutes for a validation dataset. Where it fits: autologous programs where reproducibility across donors and sites is the binding constraint, and hospital systems thinking about localized production. Where it doesn't: anyone comparing allogeneic off-the-shelf developers (different lane entirely), anyone who needs released product specs or contracted terms this quarter, and any patient looking for treatment — these therapies are pre-commercial.